VBI researchers develop new method for breast cancer biomarker... ( Blacksburg Va. -- Three researchers ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

VBI researchers develop new method for breast cancer biomarker discovery

Date:6/9/2009

Blacksburg, Va. -- Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.

VBI Assistant Professor Iuliana Lazar, along with VBI Professor Ina Hoeschele and VBI Postdoctoral Associate Jenny Armenta, developed the method*, which uses proteomic technologies for fast biomarker fingerprinting in complex cellular extracts. The goal of biomarker discovery and screening is to identify changes in the levels of key proteins in the cell in response to the onset or development of a disease. The scientific community has invested extensive efforts into the development of methods that would allow for the sensitive screening of large panels of biomarkers, instead of just one at a time. This type of research promises to advance the capabilities of such techniques for early cancer detection, which could significantly reduce the mortality rate from diseases like cancer.

At the heart of the new method are three innovative developments A data acquisition strategy that permits analysis of different cell states and replicates; an advanced way to filter or process the data; and a novel statistical method that allows the experimental data to be checked and their relevance confirmed. The team used the method for proteomic profiling of MCF-7 breast cancer cells cultured in estradiol, a steroid hormone, and tamoxifen, a non-steroidal drug commonly prescribed in hormonal breast cancer therapy.

The work resulted in the identification of 16 differentially expressed proteins, which demonstrated the effectiveness of the method for biomarker discovery and also allowed for the establishment of a link between the proteins and
'/>"/>

Contact: Susan Bland
subland@vbi.vt.edu
540-231-7912
Virginia Tech
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins

Post Your Comments:

[0] NICE guidelines ration affordable osteoporosis drugs [0] Menopause Often Means Worsening Cholesterol [0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [1] New Board Gains Control of U.S. Shanghai Chemical Corporation [0] Surgery on beating heart thanks to robotic helping hand

Other Medicine News:Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2 Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3 Health News:Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3 Health News:National study finds youth baseball-related injuries down 25 percent 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 2 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 3 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 4

Cogdell Spencer Announces Commencement of Common Stock Offering Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception National study finds youth baseball-related injuries down 25 percent More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer

Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4 Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4

[0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders [0] Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg [0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer

Other Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 2 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 3

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

Medicine Products:

Continuous Flow Cystoscopes Prolieve™ Thermodilatation System The Prostatron® System The Targis® System

VBI researchers develop new method for breast cancer biomarker...( Blacksburg Va. -- Three researchers ...),Health